lenz therapeutics inc com - LENZ

LENZ

Close Chg Chg %
33.91 0.41 1.21%

Closed Market

34.32

+0.41 (1.21%)

Volume: 85.10K

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Company Overview: lenz therapeutics inc com - LENZ

LENZ Key Data

Open

$34.00

Day Range

33.10 - 34.62

52 Week Range

14.42 - 38.93

Market Cap

$932.56M

Shares Outstanding

27.50M

Public Float

22.36M

Beta

0.35

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$7.07

Yield

0.00%

Dividend

$1.03

EX-DIVIDEND DATE

Mar 22, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

176.30K

 

LENZ Performance

1 Week
 
3.37%
 
1 Month
 
27.02%
 
3 Months
 
52.53%
 
1 Year
 
N/A
 
5 Years
 
N/A
 

LENZ Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About lenz therapeutics inc com - LENZ

LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. It offers eye drop product treatment for presbyopia. The company was founded by James McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ At a Glance

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Solana Beach, California 92075
Phone 1-858-925-7000 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -124,651,000.00
Sector Health Technology Employees 6
Fiscal Year-end 12 / 2024
View SEC Filings

LENZ Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 0.828
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.511
Enterprise Value to Sales N/A
Total Debt to Enterprise Value -0.01

LENZ Efficiency

Revenue/Employee N/A
Income Per Employee -20,775,166.667
Receivables Turnover N/A
Total Asset Turnover N/A

LENZ Liquidity

Current Ratio 39.196
Quick Ratio 39.196
Cash Ratio 38.745

LENZ Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -48.848
Return on Equity -51.952
Return on Total Capital -67.766
Return on Invested Capital -51.755

LENZ Capital Structure

Total Debt to Total Equity 0.197
Total Debt to Total Capital 0.197
Total Debt to Total Assets 0.192
Long-Term Debt to Equity 0.042
Long-Term Debt to Total Capital 0.042
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Lenz Therapeutics Inc Com - LENZ

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
121.00K 734.00K 8.35M 2.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
121.00K 734.00K 8.35M 2.41M
Depreciation
121.00K 734.00K 8.35M 2.41M
Amortization of Intangibles
- - - -
-
COGS Growth
- +506.61% +1,037.06% -71.16%
Gross Income
(121.00K) (734.00K) (8.35M) (2.41M)
Gross Income Growth
- -506.61% -1,037.06% +71.16%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
13.38M 59.71M 97.29M 70.70M
Research & Development
9.12M 37.93M 64.44M 29.73M
Other SG&A
4.26M 21.78M 32.85M 40.97M
SGA Growth
+46,034.48% +346.29% +62.95% -27.33%
Other Operating Expense
- - - -
-
Unusual Expense
- 54.83M 10.32M 62.08M
EBIT after Unusual Expense
(68.33M) (70.76M) (105.64M) (135.19M)
Non Operating Income/Expense
- - 4.59M 10.54M
-
Non-Operating Interest Income
- - 4.59M 10.95M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 40.00K
-
Interest Expense Growth
- - -50.00% -100.00%
-
Gross Interest Expense
- - - 40.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(68.37M) (70.76M) (101.05M) (124.65M)
Pretax Income Growth
-62,627.52% -3.49% -42.81% -23.35%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(68.37M) (70.76M) (101.05M) (124.65M)
Minority Interest Expense
- - - -
-
Net Income
(68.37M) (70.76M) (101.05M) (124.65M)
Net Income Growth
-62,627.52% -3.49% -42.81% -23.35%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(68.37M) (70.76M) (101.05M) (124.65M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(68.37M) (70.76M) (101.05M) (124.65M)
EPS (Basic)
-8.2407 -8.5384 -12.8908 -15.304
EPS (Basic) Growth
-62,329.55% -3.61% -50.97% -18.72%
Basic Shares Outstanding
8.30M 8.29M 7.84M 8.15M
EPS (Diluted)
-8.2407 -8.5384 -12.8908 -15.304
EPS (Diluted) Growth
-62,329.55% -3.61% -50.97% -18.72%
Diluted Shares Outstanding
8.30M 8.29M 7.84M 8.15M
EBITDA
(13.38M) (59.71M) (97.29M) (70.70M)
EBITDA Growth
-46,034.48% -346.29% -62.95% +27.33%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 36.714
Number of Ratings 7 Current Quarters Estimate -0.409
FY Report Date 12 / 2024 Current Year's Estimate -2.823
Last Quarter’s Earnings -0.38 Median PE on CY Estimate N/A
Year Ago Earnings -7.846 Next Fiscal Year Estimate -2.346
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 3 7 7
Mean Estimate -0.41 -0.51 -2.82 -2.35
High Estimates -0.39 -0.48 -1.82 -1.19
Low Estimate -0.45 -0.57 -4.76 -3.12
Coefficient of Variance -5.81 -10.19 -46.54 -26.20

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 1 1 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Lenz Therapeutics Inc Com - LENZ

Date Name Shares Transaction Value
May 16, 2024 Daniel R. Chevallard Chief Financial Officer 3,188 Open market or private purchase of non-derivative security Non-derivative transaction at $15.68 per share 49,987.84
May 15, 2024 James W. McCollum Director 525,565 Open market or private purchase of non-derivative security Non-derivative transaction at $15.99 per share 8,403,784.35
Apr 9, 2024 James W. McCollum Director 477,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 Frédéric Guerard Director 27,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 Frédéric Guerard Director 23,571 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 Frédéric Guerard Director 30,897 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 Zach Scheiner Director 27,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 Versant Venture Management LLC 842,162 Other acquisition or disposition 0.00
Apr 9, 2024 Shelley B. Thunen Director 27,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 James W. McCollum Director 27,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 James W. McCollum Director 6,575 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 James W. McCollum Director 494,233 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $15.03 per share 7,428,321.99
Apr 9, 2024 RA Capital Management LP Director 2,386,301 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 RA Capital Management LP Director 27,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 RA Capital Management LP Director 5,371 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 RA Capital Management LP Director 10,580 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 RA Capital Management LP Director 54,582 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2024 RA Capital Management LP Director 694,755 Open market or private purchase of non-derivative security Non-derivative transaction at $15.03 per share 10,442,167.65
Apr 9, 2024 RA Capital Management LP Director 3,319,339 Open market or private purchase of non-derivative security Non-derivative transaction at $15.03 per share 49,889,665.17
Apr 9, 2024 RA Capital Management LP Director 164,729 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Lenz Therapeutics Inc Com in the News